Biomarkers and severe asthma: A critical appraisal

Clinical and Molecular Allergy

Volumn 13, Issue 1, 2015, Pages

  Chiappori, Alessandra ^a   De Ferrari, Laura ^a   Folli, Chiara ^a   Mauri, Pierluigi ^b   Riccio, Anna Maria ^a   Canonica, Giorgio Walter ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b INSTITUTE OF BIOMEDICAL TECHNOLOGIES   (Italy)

Author keywords

Allergic inflammation; Biomarkers; Eosinophil; Exhaled nitric oxide; Galectin; Monoclonal antibodies; Neutrophil; Periostin; Severe asthma

Indexed keywords

BIOLOGICAL MARKER; ECALECTIN; EOTAXIN; GALECTIN 3; INDUCIBLE NITRIC OXIDE SYNTHASE; LEUKOTRIENE B4; LIPOXIN A; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR RUNX2;

ASTHMA; DISEASE SEVERITY; EOSINOPHIL COUNT; EXHALED BREATH CONDENSATE; FORCED EXPIRATORY VOLUME; FRACTIONAL EXHALED NITRIC OXIDE; HUMAN; NEUTROPHIL CHEMOTAXIS; NEUTROPHIL COUNT; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PREDICTIVE VALUE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INDUCTION; RESPIRATORY TRACT PARAMETERS; REVIEW; SENSITIVITY AND SPECIFICITY;

EID: 84942770527     PISSN: None     EISSN: 14767961     Source Type: Journal    
DOI: 10.1186/s12948-015-0027-7     Document Type: Review

References (143)

1. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ et al (2014) International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 43:343-373
2. American Thoracic Society (2000) Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med 162:2341-2351
3. Moore WC, Bleecker ER, Curran-Everett D, Erzurum SC, Ameredes BT, Bacharier L et al (2007) Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 119:405-413
4. Chen H, Blanc PD, Hayden ML, Bleecker ER, Chawla A, Lee JH et al (2008) Assessing productivity loss and activity impairment in severe or difficult-to-treat asthma. Value Health 11:231-239
5. Wenzel SE (2012) Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 18:716-725
6. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A et al (2009) T-helper type 2-driven inflammation defines major subphenptypes of asthma. Am J Respir Crit Care Med 180:388-395
7. Trejo Bittar HE, Yousem SA, Wenzel SE (2015) Pathobiology of severe asthma. Ann Rev Pathol 10:511-545
8. Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X et al (2010) Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am J Respir Crit Care Med 181:315-323
9. Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF, Barnes PJ (1999) Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 160:1532-1539
10. Gibson PG, Simpson JL, Saltos N (2001) Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest 119:1329-1336
11. Rossall MRW, Cadden PA, Molphy SD, Plumb J, Singh D (2014) Repeatability of induced sputum measurements in moderate to severe asthma. Respir Med 108:1566-1568
12. Nair P, Gaga M, Zervas E, Alagha K, Hargreave FE, O'Byrne PM et al (2012) Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin Exp Allergy 42:1097-1103
13. Schleimer RP (2004) Glucocorticoids suppress inflammation but spare innate immune responses in airway epithelium. Proc Am Thorac Soc 1:222-230
14. Barnes PJ, Adcock IM (2009) Glucocorticoid resistance in inflammatory diseases. Lancet 373:1905-1917
15. Hosoki K, Boldogh I, Sur S (2015) Innate responses to pollen allergens. Curr Opin Allergy Clin Immunol 15:79-88
16. Boldogh I, Bacsi A, Choudhury BK, Dharajiya N, Alam R, Hazra TK (2005) ROS generated by pollen NADPH oxidase provide a signal that augments antigen-induced allergic airway inflammation. J Clin Invest 115:2169-2179
17. Hosoki K, Aguilera-Aguirre L, Brasier AR, Kurosky A, Boldogh I, Sur S (2015) Pollen-induced innate recruitment of neutrophils facilitates induction of allergic sensitization and airway inflammation. Am J Respir Cell Mol Biol. doi: 10.1165/rcmb.2015-0044OC
18. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ (2010) HMGB1 and RAGE in inflammation and cancer. Ann Rev Immunol 28:367-388
19. Sukkar MB, Wood LG, Tooze M, Simpson JL, McDonald VM, Gibson PG et al (2012) Soluble RAGE is deficient in neutrophilic asthma and COPD. Eur Respir J 39:721-729
20. Gómez-Gaviro M, Domínguez-Luis M, Canchado J, Calafat J, Janssen H, Lara-Pezzi E et al (2007) Expression and regulation of the metalloproteinase ADAM-8 during human neutrophil pathophysiological activation and its catalytic activity on L-selectin shedding. J Immunol 178:8053-8063
21. Johansson MW, Lye MH, Barthel SR, Duffy AK, Annis DS, Mosher DF (2004) Eosinophils adhere to vascular cell adhesion molecule-1 via podosomes. Am J Respir Cell Mol Biol 31:413-422
22. Paulissen G, Rocks N, Quesada-Calvo F, Gosset P, Foidart JM, Noel A et al (2006) Expression of ADAMs and their inhibitors in sputum from patients with asthma. Mol Med 12:171-179
23. Foley SC, Mogas AK, Olivenstein R, Fiset PO, Chakir J, Bourbeau J et al (2007) Increased expression of ADAM-33 and ADAM-8 with disease progression in asthma. J Allergy Clin Immunol 119:863-871
24. Oreo KM, Gibson PG, Simpson JL, Wood LG, McDonald VM, Baines KJ (2013) Sputum ADAM-8 expression in increased in severe asthma and COPD. Clin Exp Allergy 44:342-352
25. Flood-Page P, Menzies-Gow A, Phipps S, Ying S, Wangoo A, Ludwig MS et al (2003) Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Investig 112:1029-1036
26. Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID (2002) Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 57:875-879
27. Miranda C, Busacker A, Balzar S, Trudeau J, Wenzel SE (2004) Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 113:101-108
28. Hilvering B, Pavord ID (2015) What goes up must come down: biomarkers and novel biologicals in severe asthma. Clin Exp Allergy 45:1162-1169
29. Wenzel SE, Schwartz LB, Langmack EL, Halliday JL, Trudeau JB, Gibbs RL et al (1999) Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 160:1001-1008
30. Dweik RA, Sorkness RL, Wenzel S, Hammel J, Curran-Everett D, Comhair SA et al (2010) Use of exhaled nitric oxide measurement to identify a reactive, at risk phenotype among patients with asthma. Am J Respir Crit Care Med 181:1033-1041
31. Riccio AM, Dal Negro RW, Micheletto C, De Ferrari L, Folli C, Chiappori A et al (2012) Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients. Int J Immunopathol Pharmacol 25:475-484
32. Zietkowski Z, Skiepko R, Tomasiak-Lozowska MM, Bodzenta-Lukaszyk A (2010) Anti-IgE therapy with omalizumab decreases endothelin-1 in exhaled breath condensate of patients with severe persistent allergic asthma. Respiration 80:534-542
33. Zietkowski Z, Skiepko R, Tomasiak-Lozowska MM, Lenczewska D, Bodzenta-Lukaszyk A (2011) RANTES in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy. Int Arch Allergy Immunol 154:25-32
34. Skiepko R, Zietkowski Z, Lukaszyk M, Budny W, Skiepko U, Milewski R et al (2014) Changes in blood eosinophilia during omalizumab therapy as a predictor of asthma exacerbation. Postepy Dermatol Alergol 31:305-309
35. Tajiri T, Niimi A, Matsumoto H, Ito I, Oguma T, Otsuka K et al (2014) Comprehensive efficacy of omalizumab for severe refractory asthma: a time-series observational study. Ann Allergy Asthma Immunol 113(470-5):e2
36. Gouder C, West LM, Montefort S (2015) The real-life clinical effects of 52 weeks of omalizumab therapy for severe persistent allergic asthma. Int J Clin Pharm 37:36-43
37. Mauri P, Riccio AM, Rossi R, DiSilvestre D, Benazzi L, DeFerrari L et al (2014) Proteomics of bronchial biopsies: galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients. Immunol Lett 162(1 Pt A):2-10
38. Wadsworth S, Sin D, Dorscheid D (2011) Clinical update on the use of biomarkers of airway inflammation in the management of asthma. J Asthma Allergy 4:77-86
39. Eltboli O, Brightling CE (2013) Eosinophils as diagnostic tools in chronic lung disease. Expert Rev Respir Med 7:33-42
40. Szefler SJ, Wenzel S, Brown R, Erzurum SC, Fahy JV, Hamilton RG et al (2012) Asthma outcomes: biomarkers. J Allergy Clin Immunol 129(Suppl):9-23
41. Newby C, Agbetile J, Hargadon B, Monteiro W, Green R, Pavord I et al (2014) Lung function decline and variable airway inflammatory pattern: longitudinal analysis of severe asthma. J Allergy Clin Immunol 134:287-294
42. McGrath KW, Icitovic N, Boushey HA, Lazarus SC, Sutherland ER, Chinchilli VM et al (2012) A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med 185:612-619
43. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON et al (2012) Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380:651-659
44. Malinovschi A, Fonseca JA, Jacinto T, Alving K, Janson C (2013) Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects. J Allergy Clin Immunol 132:821-827
45. Katz LE, Gleich GJ, Hartley BF, Yancey SW, Ortega HG (2014) Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma. Ann Am Thorac Soc 11:531-536
46. Djukanović R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF et al (2004) Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 170:583-593
47. Hanania NA, Wenzel S, Rosen K, Hsieh HJ, Mosesova S, Choy DF et al (2013) Exploring the effects of Omalizumab in allergic asthma. An analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 187:804-811
48. Conroy DM, Williams TJ (2001) Eotaxin and the attraction of eosinophils to the asthmatic lung. Respir Res 2:150-156
49. Zietowski Z, Tomasiek-Lozowska MM, Skiepko R, Zietowska E, Bodzenta-Lukaszyk A (2010) Eotaxin-1 in exhaled breath condensate of stable and unstable asthma patients. Respir Res 11:110
50. Kim CK, Kita H, Callaway Z, Kim HB, Choi J, Fujisawa T et al (2010) The roles of a Th2 cytokine and CC chemokine in children with stable asthma: potential implication in eosinophil degranulation. Pediatr Allergy Immunol 21:e697-e704
51. Wu D, Zhou J, Bi H, Li L, Gao W, Huang M et al (2014) CCL-11 as a potential diagnostic marker for asthma? J Asthma 51:847-854
52. Minshall EM, Leung DY, Martin RJ, Song LY, Cameron L, Ernst P et al (1997) Eosinophil-associated TGF-β1 mRNA expression and airways fibrosis in bronchial asthma. Am J Respir Cell Mol Biol 17:326-333
53. Harrop CA, Gore RB, Evans CM, Thornton DJ, Herrick SE (2013) TGF-ß2 decreases baseline and IL-13-stimulated mucin production by primary human bronchial epithelial cell. Exp Lung Res 39:39-47
54. Al-Alawi M, Hassan T, Chotirmall SH (2014) Transforming growth factor ß and severe asthma: a perfect storm. Respir Med 108:1409-1423
55. Lane C, Knight D, Burgess S, Franklin P, Horak F, Legg J et al (2004) Epithelial inducible nitric oxide synthase activity is the major determinant of nitric oxide concentration in exhaled breath. Thorax 59:757-760
56. Van Den Toorn LM, Overbeek SE, De Jongste JC, Leman K, Hoogsteden HC, Prins JB (2001) Airway inflammation is present during clinical remission of atopic asthma. Am J Respir Crit Care Med 164:2107-2113
57. Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO et al (2011) on behalf of the American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FeNO) for Clinical Applications. An Official ATS Clinical Practice Guideline: Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. Am J Respir Crit Care Med 184:602-615
58. Yang S, Park J, Lee YK, Kim H, Hahn YS (2015) Association of longitudinal fractional exhaled nitric oxide measurements with asthma control in atopic children. Respir Med 109:572-579
59. Gemicioglu B, Musellim B, Dogan I, Guven K (2014) Fractional exhaled nitric oxide (FeNo) in different asthma phenotypes. Allergy Rhinol 5:157-161
60. Sippel JM, Holden WE, Tilles SA, O'Hollaren M, Cook J, Thukkani N et al (2000) Exhaled nitric oxide levels correlate with measures of disease control in asthma. J Allergy Clin Immunol 106:645-650
61. Peirsman EJ, Carvelli TJ, Hage PY, Hanssens LS, Pattyn L, Raes MM et al (2014) Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. Pediatr Pulmonol 49:624-631
62. Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH et al (2011) Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 364:1005-1015
63. Sorkness CA, Wildfire JJ, Calatroni A, Mitchell HE, Busse WW, O'Connor GT et al (2013) Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents. J Allergy Clin Immunol Pract 1:163-171
64. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F et al (2013) Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 368:2455-2466
65. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A et al (2009) Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 360:973-984
66. Hamid Q (2003) Gross pathology and hystopatology of asthma. J Allergy Clin Immunol 111:431-432
67. Dent AG, Sutedja TG, Zimmerman PV (2013) Exhaled breath analysis for lung cancer. J Thorac 5:540-550
68. Horváth I, Hunt J, Barnes PJ, Alving K, Antczak A, Baraldi E et al (2005) ATS/ERS Task Force on Exhaled Breath Condensate. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J 26:523-548
69. Corhay JL, Moermans C, Henket M, Nguyen Dang D, Duysinx B, Louis R (2014) Increased of exhaled breath condensate neutrophil chemotaxis in acute exacerbation of COPD. Respir Res 15:115
70. Schwarz K, Biller H, Windt H, Koch W, Hohlfeld JM (2015) Characterization of exhaled particles from the human lungs in airway obstruction. J Aerosol Med Pulm Drug Deliv 28:52-58
71. Tseliou E, Bessa V, Hillas G, Delimpoura V, Papadaki G, Roussos C et al (2010) Exhaled nitric oxide and exhaled breath condensate pH in severe refractory asthma. Chest 138:107-113
72. Liu L, Teague WG, Erzurum S, Fitzpatrick A, Mantri S, Dweik RA et al (2011) National Heart, Lung, and Blood Institute Severe Asthma Research Program (SARP). Determinants of exhaled breath condensate pH in a large population with asthma. Chest 139:328-336
73. Kazani S, Planaguma A, Ono E, Bonini M, Zahid M, Marigowda G (2013) Exhaled breath condensate eicosanoid levels associate with asthma and its severity. J Allergy Clin Immunol 132:547-553
74. Comhair SA, Erzurum SC (2010) Redox control of asthma: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal 12:93-124
75. Tomasiak-Lozowska MM, Zietkowski Z, Przeslaw K, Tomasiak M, Skiepko R, Bodzenta-Lukaszyk A (2012) Inflammatory markers and acid-base equilibrium in exhaled breath condensate of stable and unstable asthma patients. Int Arch Allergy Immunol 159:121-129
76. Mattarucchi E, Baraldi E, Guillou C (2012) Metabolomics applied to urine samples in childhood asthma; differentiation between asthma phenotypes and identification of relevant metabolites. Biomed Chromatogr 26:89-94
77. Di Gangi IM, Pirillo P, Carraro S, Gucciardi A, Naturale M, Baraldi E et al (2012) Online trapping and enrichment ultra performance liquid chromatography-tandem mass spectrometry method for sensitive measurement of "arginine-asymmetric dimethylarginine cycle" biomarkers in human exhaled breath condensate. Anal Chim Acta 754:67-74
78. Carraro S, Giordano G, Reniero F, Carpi D, Stocchero M, Sterk PJ et al (2013) Asthma severity in childhood and metabolomic profiling of breath condensate. Allergy 68:110-117
79. Baraldi E, Carraro S, Giordano G, Reniero F, Perilongo G, Zacchello F (2009) Metabolomics: moving towards personalized medicine. Ital J Pediatr 35:30
80. Fitzpatrick AM, Park Y, Brown LA, Jones DP (2014) Children with severe asthma have unique oxidative stress-associated metabolomic profiles. J Allergy Clin Immunol 133:258-261
81. Conway SJ, Izuhara K, Kudo Y, Litvin J, Markwald R, Ouyang G et al (2014) The role of periostin in tissue remodeling across health and disease. Cell Mol Life Sci 71:1279-1288
82. Takayama G, Arima K, Kanaji T, Toda S, Tanaka H, Shoji S et al (2006) Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol 118:98-104
83. Izuhara K, Arima K, Ohta S, Suzuki S, Inamitsu M, Yamamoto K (2014) Periostin in allergic inflammation. Allergol Int 63:143-151
84. Yuyama N, Davies DE, Akaiwa M, Matsui K, Hamasaki Y, Suminami Y et al (2002) Analysis of novel disease-related genes in bronchial asthma. Cytokine 19:287-296
85. Sidhu SS, Yuan S, Innes AL, Kerr S, Woodruff PG, Hou L et al (2010) Roles of epithelial cell-derived periostin in TFG-beta activation, collagen production, and collagen gel elasticity in asthma. Proc Natl Acad Sci USA 107:14170-14175
86. Blanchard C, Mingler MK, McBride M, Putnam PE, Collins MH, Chang G et al (2008) Periostin facilitated eosinophil tissue infiltration in allergic lung and esophageal responses. Mucosal Immunol 1:289-296
87. Masuoka M, Shiraishi H, Ohta S, Suzuki S, Arima K, Aoki S et al (2012) Periostin promotes chronic allergic inflammation in response to Th2 cytokines. J Clin Invest 122:2590-2600
88. Matsumoto H (2014) Serum periostin: a novel biomarker for asthma management. Allergol Int 63:153-160
89. Jia G, Erickson RW, Choy DF, Mosesova S, Wu LC, Solberg OD et al (2012) Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol 130:647-654
90. Kanemitsu Y, Matsumoto H, Izuhara K, Tohda Y, Kita H, Horiguchi T et al (2013) Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids. J Allergy Clin Immunol 132:305-312
91. Parulekar AD, Mustafa AA, Hanania NA (2014) Periostin, a novel biomarker of Th2-driven asthma. Curr Opin Pulm Med 20:60-65
92. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR et al (2011) Lebrikizumab treatment in adults with asthma. N Engl J Med 365:1088-1098
93. Bobolea I, Barranco P, Del Pozo V, Romero D, Sanz V, Lopez-Carrasco V et al (2015) Sputum periostin in patients with different severe asthma phenotypes. Allergy. doi: 10.1111/all.12580
94. Kou K, Okawa T, Yamaguchi Y, Ono J, Inoue Y, Kohno M et al (2014) Periostin levels correlate with disease severity and chronicity in patients with atopic dermatitis. Br J Dermatol 171:283-291
95. Ohta N, Kurakami K, Ishida A, Furukawa T, Saito F, Kakehata S et al (2012) Clinical and pathological characteristics of IgG4-related sclerosing sialadenitis. Laryngoscope 122:572-577
96. Ishida A, Ohta N, Suzuki Y, Kakehata S, Okubo K, Ikeda H et al (2012) Expression of pendrin and periostin in allergic rhinitis and chronic rhinosinusitis. Allergol Int 61:589-595
97. Nishizawa H, Matsubara A, Nakagawa T, Ohta N, Izuhara K, Shirasaki T et al (2012) The role of periostin in eosinophilic otitis media. Acta Otolaryngol 132:838-844
98. Okamoto M, Hoshino T, Kitasato Y, Sakazaki Y, Kawayama T, Fujimoto K et al (2011) Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias. Eur Respir J 37:1119-1127
99. Uchida M, Shiraishi H, Ohta S, Arima K, Taniguchi K, Suzuki S et al (2012) Periostin, a matricellular protein, plays a role in the induction of chemokines in pulmonary fibrosis. Am J Respir Cell Mol Biol 46:677-686
100. Stankovic KM, Goldsztein H, Reh DD, Platt MP, Metson R (2008) Gene expression profiling of nasal polyps associated with chronic sinusitis and aspirin-sensitive asthma. Laryngoscope 118:881-889
101. Fujimoto K, Kawaguchi T, Nakashima O, Ono J, Kawaguchi A, Tonan T et al (2011) Periostin, a matrix protein, has potential as a novel serodiagnostic marker for cholangiocarcinoma. Oncol Rep 25:1211-1216
102. Sirica AE, Almenara JA, Li C (2014) Periostin in intrahepatic cholangiocarcinoma: pathobiological insights and clinical implications. Exp Mol Pathol 97:515-524
103. Zhu M, Fejzo MS, Anderson L, Dering J, Ginther C, Ramos L et al (2010) Periostin promotes ovarian cancer angiogenesis and metastasis. Gynecol Oncol 119:337-344
104. Ryner L, Guan Y, Firestein R, Xiao Y, Choi Y, Rabe C et al (2015) Up-regulation of periostin and reactive stroma is associated with primary chemoresistance and predicts clinical outcomes in epithelial ovarian cancer. Clin Cancer Res. pii: clincanres.3111.2014
105. Xiao ZM, Wang XY, Wang AM (2013) Periostin induces chemoresistance in colon cancer cells through activation of the PI3 K/Akt/survivin pathway. Biotechnol Appl Biochem. doi: 10.1002/bab.1193
106. Erkan M, Kleeff J, Gorbachevski A, Reiser C, Mitkus T, Esposito I et al (2007) Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. Gastroenterology 132:1447-1464
107. Baril P, Gangeswaran R, Mahon PC, Caulee K, Kocher HM, Harada T et al (2007) Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3k pathway. Oncogene 26:2082-2094
108. Kotobuki Y, Yang L, Serada S, Tanemura A, Yang F, Nomura S et al (2014) Periostin accelerates human malignant melanoma progression by modifying the melanoma microenviroment. Pigment Cell Melanoma Res 27:630-639
109. Kudo Y, Iizuka S, Yoshida M, Nguyen PT, Siriwardena SB, Tsunematsu T et al (2012) Periostin directly and indirectly promotes tumor lymphangiogenesis of head and neck cancer. PLoS One. doi: 10.1371/journal.pone.0044488
110. Zhou W, Ke SQ, Huang Z, Flavahan W, Fang X, Paul J et al (2015) Periostin secreted by glioblastoma stem cells recruits M2 tumor-associated macrophage and promotes malignant growth. Nat Cell Biol 17:170-182
111. Xu D, Xu H, Ren Y, Liu C, Wang X, Zhang H et al (2012) Cancer stem cell-related gene periostin: a novel prognostic marker for breast cancer. PLoS One 7:e46670
112. Takanami I, Abiko T, Koizumi S (2008) Expression of periostin in patients with non-small cell lung cancer: correlation with angiogenesis and lymphangiogenesis. Int J Biol Markers 23:182-186
113. Oku E, Kanaji T, Takata Y, Oshima K, Seki R, Morishige S et al (2008) Periostin and bone marrow fibrosis. Int J Hematol 88:57-63
114. Kashima TG, Nishiyama T, Shimazu K, Shimazaki M, Kii I, Grigoriadis AE et al (2009) Periostin, a novel marker of intramembranous ossification, is expressed in fibrous dysplasia and in c-Fos-overexpressing bone lesions. Hum Pathol 40:226-237
115. Yamaguchi Y, Ono J, Masuoka M, Ohtta S, Izuhara K, Ikezawa Z et al (2013) Serum periostin levels are correlated with progressive skin sclerosis on patients with systemic sclerosis. Br J Dermatol 168:717-725
116. Ishikawa K, Yoshida S, Nakao S, Nakama T, Kita T, Asato R et al (2014) Periostin promotes the generation of fibrous membranes in proliferative vitreoretinopathy. FASEB J 28:131-142
117. Arima K, Ohta S, Takagi A, Shiraishi H, Masuoka M, Ontsuka K et al (2015) Periostin contributes to epidermal hyperplasia in psoriasis common to atopic dermatitis. Allergol Int 64:41-48
118. Sen K, Lindermeyer MT, Gaspert A, Eichinger F, Neusser MA, Kretzler M et al (2011) Periostin is induced in glomerular injury and expressed de novo in interstitial renal fibrosis. Am J Pathol 179:1756-1767
119. Bible E (2014) Polycystic kidney disease: Periostin is involved in cell proliferation and interstitial fibrosis in polycystic kidney disease. Nat Rev Nephrol 10:66
120. Wantanasiri P, Satirapoj B, Charoenpitakchai M, Aramwit P (2015) Periostin: a novel tissue biomarker correlates with chronicity index and renal function in lupus nephritis patients. Lupus. pii:0961203314566634
121. Huang Y, Liu W, Xiao H, Maitikabili A, Lin Q, Wu T et al (2015) Matricellular protein periostin contributes to hepatic inflammation and fibrosis. Am J Pathol 185:786-797
122. Zhao S, Wu H, Xia W, Chen X, Zhu S, Zhang S et al (2014) Periostin expression is upregulated and associated with myocardical fibrosis in human failing hearts. J Cardiol 63:373-378
123. Nair P, Kraft M (2012) Serum periostin as a marker of Th2-dependent eosinophilic airway inflammation. J Allergy Clin Immunol 130:655-656
124. Ruan K, Bao S, Ouyang G (2009) The multifaceted role of periostin in tumorigenesis. Cell Mol Life Sci 66:2219-2230
125. Ebrahim AH, Alalawi Z, Mirandola L, Rakhshanda R, Dahlbeck S, Nguyen D et al (2014) Galectins in cancer: carcinogenesis, diagnosis and therapy. Ann Transl Med 2:88
126. Meijers WC, Januzzi JL, DeFilippi C, Adourian AS, Shah SJ, van Veldhuisen DJ et al (2014) Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials. Am Heart J 167:853-860
127. Panjwani N (2014) Role of galectins in re-epithelialization of wounds. Ann Transl Med 2:89
128. Schattner M (2014) Platelets and galectins. Ann Transl Med 2:85
129. Sziksz E, Kozma GT, Pállinger E, Komlósi ZI, Adori C, Kovács L et al (2010) Galectin-9 in allergic airway inflammation and hyper-responsiveness in mice. Int Arch Allergy Immunol 151:308-317
130. Niki T, Tsutsui S, Hirose S, Aradono S, Sugimoto Y, Takeshita K et al (2009) Galectin-9 is a high affinity IgE-binding lectin with anti-allergic effect by blocking IgE-antigen complex formation. J Biol Chem 284:32344-32352
131. Katoh S, Shimizu H, Obase Y, Oomizu S, Niki T, Ikeda M et al (2013) Preventive effect of galectin-9 on double-stranded RNA-induced airway hyperresponsiveness in an exacerbation model of mite antigen-induced asthma in mice. Exp Lung Res 39:453-462
132. Di Lella S, Sundblad V, Cerliani JP, Guardia CM, Estrin DA, Vasta GR et al (2011) When galectins recognize glycans: from biochemistry to physiology and back again. Biochemistry 50:7842-7857
133. Newlaczyl AU, Yu LG (2011) Galectin-3 a jack-of-all-trades in cancer. Cancer Lett 313:123-128
134. Hsu DK, Zuberi RI, Liu FT (1992) Biochemical and biophysical characterization of human recombinant IgE-binding protein, an S-type animal lectin. J Biol Chem 267:14167-14174
135. Zuberi RI, Hsu DK, Kalayci O, Chen HY, Sheldon HK, Yu L et al (2004) Critical role for galectin-3 in airway inflammation and bronchial hyperresponsiveness in a murine model of asthma. Am J Pathol 165:2045-2053
136. López E, del Pozo V, Miguel T, Sastre B, Seoane C, Civantos E et al (2006) Inhibition of chronic airway inflammation and remodeling by galectin-3 gene therapy in a murine model. J Immunol 176:1943-1950
137. Pilette C, Colinet B, Kiss R, André S, Kaltner H, Gabius HJ (2007) Increased galectin-3 expression and intra-epithelial neutrophils in small airways in severe COPD. Eur Respir J 29:914-922
138. Nishi Y, Sano H, Kawashima T, Okada T, Kuroda T, Kikkawa K et al (2007) Role of galectin-3 in human pulmonary fibrosis. Allergol Int 56:57-65
139. Gao P, Gibson PG, Baines KJ, Yang I, Upham JW, Reynolds PN et al (2015) Anti-inflammatory deficiencies in neutrophilic asthma: reduced galectin-3 and IL-1RA/IL-1β. Respir Res 16:5
140. Baines KJ, Simpson JL, Wood LG, Scott RJ, Fibbens NL, Powell H et al (2014) Sputum gene expression signature of 6 biomarkers discriminates asthma inflammatory phenotypes. J Allergy Clin Immunol 133:997-1007
141. George BJ, Reif DM, Gallagher JE, Williams-DeVane CR, Heidenfelder BL, Hudgens EE et al (2015) Data-driven asthma endotypes defined from blood biomarker and gene expression data. PLoS One 10:e0117445
142. Christenson SA, Steiling K, van den Berge M, Hijazi K, Hiemstra PS, Postma DS et al (2015) Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 191:758-766
143. Gustafsson M, Nestor CE, Zhang H, Barabási AL, Baranzini S, Brunak S et al (2014) Modules, networks and systems medicine for understanding disease and aiding diagnosis. Genome Med 6:82